Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | GRK5 | P34947 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799872 | 0.98 | CRBN (0.51) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL725492 | 0.98 | CRBN (0.51) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL1092914 | 0.88 | CRBN (0.43) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL152602 | 0.82 | GSK3B (0.58) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL727045 | 0.78 | MB (0.41) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL8344729 | 0.77 | CRBN (0.51) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL2616880 | 0.77 | CRBN (0.51) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL17081150 | 0.77 | MB (0.58) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL6368447 | 0.77 | CRBN (0.51) | CRBNCHEK1AURKADAPK3PRKD3 | |
| SCHEMBL31248057 | 0.77 | CRBN (0.51) | CRBNCHEK1AURKADAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862737-B2 | Salts, prodrugs and polymorphs of fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2018-01-09 | — | — | US | disclosed |
| US-20140309191-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-10-16 | — | — | US | disclosed |
| US-20130150400-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-06-13 | — | — | US | disclosed |
| US-8263613-B2 | Salts, prodrugs and polymorphs of fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| EP-2125802-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2009-12-02 | — | — | EP | disclosed |
| US-20090042927-A1 | Salts, Prodrugs and Polymorphs of Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-02-12 | — | — | US | disclosed |
| WO-2008098374-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309191-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | MPI, FCGRT, GPI | CRBN 4234/4885CHEK1 4179/4885AURKA 1895/4885 |
| US-20090042927-A1 | Salts, Prodrugs and Polymorphs of Fab I Inhibitors | MPI, FCGRT, GPI | CRBN 4234/4885CHEK1 4179/4885AURKA 1895/4885 |
| US-20130150400-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | MPI, FCGRT, GPI | CRBN 4234/4885CHEK1 4179/4885AURKA 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.